Compare SDRL & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDRL | ANIP |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | SDRL | ANIP |
|---|---|---|
| Price | $34.85 | $85.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $46.25 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 768.1K | 535.8K |
| Earning Date | 02-25-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.55 | ★ 1.67 |
| Revenue | ★ $1,307,000,000.00 | $826,880,000.00 |
| Revenue This Year | $8.52 | $44.37 |
| Revenue Next Year | N/A | $9.83 |
| P/E Ratio | $63.31 | ★ $50.65 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $17.74 | $54.10 |
| 52 Week High | $38.43 | $99.50 |
| Indicator | SDRL | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 57.05 |
| Support Level | $34.61 | $75.10 |
| Resistance Level | $36.25 | $87.01 |
| Average True Range (ATR) | 1.43 | 3.30 |
| MACD | 0.01 | 0.86 |
| Stochastic Oscillator | 48.19 | 83.29 |
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.